Vitamin D deficiency is one of the most common findings in metabolic health and hormone optimization practice. But identifying the deficiency is only the beginning. The clinical value is in correcting it efficiently, monitoring the response accurately, and maintaining optimal levels over time. This article provides a practical, evidence-based framework for vitamin D dosing across the full spectrum of deficiency, insufficiency, and optimization.
CLASSIFYING THE DEFICIT: DEFICIENCY VS. INSUFFICIENCY VS. SUBOPTIMAL
Before selecting a dosing protocol, the first step is classifying the degree of deficit based on the patient's 25(OH)D level. The following framework distinguishes between the three clinical scenarios that require different approaches.
Deficiency is defined as a 25(OH)D level below 20 ng/mL. At this level, the patient has insufficient vitamin D to support basic physiologic functions including calcium absorption, bone mineralization, and immune regulation. Deficiency at this level warrants an aggressive repletion protocol rather than simply starting a maintenance dose.
Insufficiency is defined as a 25(OH)D level between 20 and 29 ng/mL. The patient has some vitamin D on board but falls below the threshold most clinicians consider adequate for general health. A structured repletion approach followed by maintenance dosing is appropriate.
Suboptimal but within reference range describes levels between 30 and 49 ng/mL. These patients are not deficient by standard criteria but fall below the functional optimal range of 50 to 80 ng/mL supported by the integrative and functional medicine literature. A higher-dose maintenance protocol is appropriate to move them into the optimal range over time.
Optimal describes levels between 50 and 80 ng/mL. Patients in this range require only a standard maintenance dose to sustain their levels, with periodic monitoring to confirm stability.
D2 VERSUS D3: WHY IT MATTERS
The distinction between ergocalciferol - vitamin D2 - and cholecalciferol - vitamin D3 - is clinically meaningful and consistently underappreciated in routine prescribing.
Vitamin D2 is the form most commonly prescribed as a high-dose prescription supplement in the United States, largely for historical reasons related to pharmaceutical manufacturing rather than clinical superiority. Vitamin D3 is the form produced naturally in human skin in response to UVB exposure and is the form found in most over-the-counter supplements.
The clinical evidence consistently favors D3 over D2 for raising and sustaining serum 25(OH)D levels. Multiple studies have demonstrated that D3 is more potent than D2 at equivalent doses, produces higher peak serum levels, and sustains those levels for longer after supplementation is stopped. A patient prescribed 50,000 IU of D2 weekly will typically achieve lower and less sustained serum levels than a patient taking an equivalent dose of D3.
For clinical practice, the practical recommendation is to use D3 - cholecalciferol - as the preferred form for both loading and maintenance supplementation. Prescription D2 formulations remain available and are sometimes used for convenience or cost reasons, but when optimizing patient outcomes is the priority, D3 is the evidence-supported choice.
LOADING PROTOCOLS FOR DEFICIENCY
Patients with true vitamin D deficiency - levels below 20 ng/mL - benefit from a loading protocol designed to rapidly replete stores before transitioning to a maintenance dose. Loading protocols use higher doses over a defined period to fill the body's vitamin D stores more efficiently than standard daily dosing alone.
A commonly used and well-supported loading approach for significant deficiency involves 50,000 IU of vitamin D3 weekly for 8 to 12 weeks, followed by a transition to daily maintenance dosing. This protocol is effective, straightforward to communicate to patients, and produces reliable repletion in most cases when compliance is maintained.
An alternative loading approach uses daily high-dose supplementation - typically 5,000 to 10,000 IU of D3 daily - for the same 8 to 12 week period. Daily dosing may achieve more consistent serum levels than once-weekly high-dose dosing in some patients and is preferred by patients who find a daily routine easier to maintain than a weekly one.
For patients with severe deficiency - levels below 10 ng/mL - or those with significant malabsorption, obesity-related sequestration, or other factors impairing repletion, higher loading doses or extended loading periods may be required. These patients warrant closer monitoring and earlier recheck labs to confirm adequate response.
MAINTENANCE DOSING AFTER REPLETION
Once a loading protocol has been completed and the patient's level has been confirmed to be within the target range on follow-up labs, the goal shifts to maintaining optimal levels with a sustainable daily dose.
The appropriate maintenance dose varies significantly between patients based on body weight, sun exposure, dietary intake, and individual absorption efficiency. A general framework for maintenance dosing is as follows.
For patients at optimal levels with adequate sun exposure and normal body weight, 2,000 IU of D3 daily is a reasonable starting maintenance dose. For patients with limited sun exposure, higher body weight, or who are on medications that affect vitamin D metabolism such as anticonvulsants or glucocorticoids, 3,000 to 5,000 IU daily is typically required to maintain optimal levels. For higher-BMI patients - particularly those in a weight loss program - 5,000 IU daily or higher may be necessary given the fat sequestration effect in higher-BMI patients.
The only reliable way to confirm that a maintenance dose is adequate for an individual patient is to recheck the 25(OH)D level after 2 to 3 months on the maintenance dose and adjust accordingly. Prescribing a maintenance dose without follow-up monitoring is a common clinical gap that leads to patients drifting back into insufficiency or deficiency over time.
CO-FACTORS: MAGNESIUM AND VITAMIN K2
Vitamin D does not function in isolation, and providers who supplement vitamin D without addressing the two most clinically relevant co-factors - magnesium and vitamin K2- are leaving meaningful clinical outcomes unaddressed.
Magnesium. Magnesium is required for the enzymatic conversion of vitamin D to its active form, 1,25-dihydroxyvitamin D. A patient who is magnesium deficient cannot fully activate the vitamin D they are taking regardless of how high their serum 25(OH)D level climbs. Magnesium deficiency is extremely common - estimated to affect up to 50 percent of the general population - and is disproportionately prevalent in the same patient populations most at risk for vitamin D deficiency. Supplementing magnesium alongside vitamin D is a straightforward clinical decision that supports optimal vitamin D activation. Magnesium glycinate or magnesium malate are preferred forms for most patients due to their superior absorption and lower likelihood of causing gastrointestinal side effects compared to magnesium oxide.
Vitamin K2. Vitamin D increases intestinal calcium absorption. Vitamin K2 - specifically the MK-7 form - activates the proteins osteocalcin and matrix GLA protein that direct absorbed calcium to bone rather than to soft tissue including arterial walls. Without adequate K2, the calcium mobilized by vitamin D repletion may deposit in arteries and other soft tissues rather than being incorporated into bone - a concern particularly relevant in older patients and those with cardiovascular risk factors. Co-supplementing vitamin K2 at 100 to 200 mcg daily alongside vitamin D is a reasonable and well-supported clinical practice for patients on significant vitamin D supplementation.
WHEN TO RECHECK: A PRACTICAL MONITORING SCHEDULE
A structured recheck schedule ensures that dosing is working and that levels remain within the target range over time. The following framework is practical and appropriate for most clinical settings.
After a loading protocol, recheck 25(OH)D approximately 8 to 12 weeks after the loading course is completed - not during the loading course - to assess whether repletion has been successful and to determine the appropriate maintenance dose.
After starting or adjusting a maintenance dose, recheck at 2 to 3 months to confirm that the new dose is producing and sustaining the target level.
For patients on stable maintenance dosing within the optimal range, annual monitoring is generally sufficient unless clinical circumstances change - significant weight gain or loss, new medications affecting vitamin D metabolism, or new symptoms suggesting deficiency recurrence.
For patients on high-dose supplementation - greater than 10,000 IU daily ā€” more frequent monitoring is appropriate given the potential for toxicity at supraphysiologic levels.
DOCUMENTING VITAMIN D MANAGEMENT
Vitamin D supplementation decisions should be documented with the same specificity as any other clinical prescription. The chart note should include the baseline 25(OH)D level, the clinical rationale for the dosing approach chosen, the specific protocol prescribed including dose, frequency, and duration, the planned recheck date, and co-factor recommendations provided to the patient.
This level of documentation demonstrates clinical intentionality, supports continuity of care, and protects the provider in the rare event that vitamin D toxicity is a concern - by establishing that dosing was evidence-based and monitoring was planned from the outset.
BOTTOM LINE
Vitamin D dosing is not a one-size-fits-all clinical decision. Matching the dosing protocol to the degree of deficit, using D3 over D2, addressing magnesium and K2 co-factor status, and following a structured recheck schedule are the elements that distinguish a clinically effective vitamin D management approach from simply writing a supplement recommendation and hoping for the best. Providers who manage vitamin D with the same intentionality they bring to hormone therapy and GLP-1 prescribing consistently achieve better patient outcomes and build stronger clinical reputations.
